Browsing Tag
Phesgo
1 post
Roche (SIX: ROP) sales rise 7% as pipeline hopes meet a near-record valuation
Roche delivered 7% constant-currency Q3 sales growth and maintained 2026 guidance as newer medicines offset patent erosion. With ROP touching a 52-week high and key medicines still awaiting regulatory decisions, pipeline conversion is becoming the next valuation test.